IPP Bureau
WHO establishes biomanufacturing training hub in South Korea
By IPP Bureau - February 23, 2022
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Merck completes acquisition of biopharma CDMO Exelead
By IPP Bureau - February 23, 2022
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Bayer highlights pharma business plans on Media Day
By IPP Bureau - February 23, 2022
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
Sanofi India posts CY2021 PAT at Rs. 944.4 Cr
By IPP Bureau - February 23, 2022
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
Biosion appoints Joel Edwards as Chief Business Officer
By IPP Bureau - February 22, 2022
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
PrecisionLife appoints Colin Stubberfield as SVP Drug Discovery
By IPP Bureau - February 22, 2022
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Formulated Solutions appoints John Maddox as COO
By IPP Bureau - February 22, 2022
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
Daewoong Pharmaceutical posts strong financials in 2021
By IPP Bureau - February 22, 2022
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Prestige BioPharma’s Tuznue receives EU-GMP certification
By IPP Bureau - February 22, 2022
Thermo Scientific offers a new portfolio of chromatography and mass spectrometry consumables
By IPP Bureau - February 22, 2022
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China
By IPP Bureau - February 22, 2022
Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.
CARsgen Therapeutics opens new U.S. cGMP facility for CAR T production
By IPP Bureau - February 22, 2022
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Abbott's CardioMEMS HF System receives USFDA approval
By IPP Bureau - February 22, 2022
New expanded indication provides patients suffering from earlier stages of heart failure access to the CardioMEMS HF System, a small implantable sensor that can flag early warning signs of worsening heart failure
Prestige BioPharma’s facility receives EU-GMP certification
By IPP Bureau - February 22, 2022
The facility will manufacture its Herceptin biosimilar, Tuznue
AIIA launches ‘Ayush Start-up Challenge’
By IPP Bureau - February 22, 2022
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
